You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources , and more. Learn More These rapidly growing stocks are begging to be bought following a more than 30% peak decline in the Nasdaq.

There’s no question that it’s been a challenging year to be an investor. Since hitting all-time closing highs in January, the iconic Dow Jones Industrial Average has entered correction territory with a loss of more than 10%, while the benchmark S&P 500 briefly dipped into a bear market .

It’s been an even tougher slog for the growth-stock-dependent Nasdaq Composite ( ^IXIC 3.33%), which tumbled as much as 31% on a peak-to-trough intraday basis, as of last weekend. This, too, firmly places the index in a bear market. Image source: Getty Images. Although the velocity of downside moves during corrections and bear markets can be scary, and big declines can pull on investors’ heartstrings, history has repeatedly shown that sizable pullbacks are the ideal time to put your money to work . Every single crash, bear market, and double-digit correction throughout history — including the Nasdaq Composite’s dot-com bubble burst — has eventually been cleared away by a bull market rally.

Right now, many of the market’s top bargains happen to be growth stocks. What follows are four exceptional growth stocks you’ll regret not buying on the Nasdaq bear market dip. Etsy

The first phenomenal growth stock well-deserving of attention from long-term investors is e-commerce platform Etsy ( ETSY 4.98%). Despite historically high inflation adversely impacting lower-income consumers at the moment, Etsy has a couple of key advantages that should help it sustain a double-digit growth rate for a long time.

The biggest differentiating factor for Etsy is the composition of its merchants. Whereas most online retail platforms are impersonal and based purely on volume, Etsy’s merchants are almost always small businesses that create unique goods or provide customizable services. There’s no platform at scale where merchants engage on a more personal level with shoppers, which is what makes Etsy so untouchable from a competitive standpoint.

Something else impressive about Etsy’s operating model has been its ability to transform casual shoppers into habitual buyers . A “habitual buyer” is someone who spends at least an aggregate of $200 over the trailing-12-month period and makes at least six separate purchases.

Even taking into account that the retail landscape has softened a bit due to inflation, Etsy saw the number of habitual buyers on its platform grow 224% between the end of 2019 (pre-pandemic) and the end of 2021. This incredible growth should allow the company to charge merchants progressively more for ads and various services.

Etsy looks like a screaming bargain at roughly 20 times Wall Street’s forward-year earnings forecast. Image source: Getty Images. Novavax

Another exceptional growth stock you’ll almost certainly regret not buying on the dip is biotech company Novavax ( NVAX 17.46%). Although Novavax delayed filing for emergency-use authorization for its COVID-19 vaccine in a number of key markets last year, thereby missing some proverbial low-hanging fruit in developed markets, the company looks poised to capitalize on its lead vaccine and other pipeline developments.

The Novavax COVID-19 vaccine, NVX-CoV2373, has a number of competitive advantages. For instance, it’s a protein-based vaccine and not messenger-RNA-based. This has the potential to encourage COVID-19 vaccine holdouts to get the jab.

What’s more, it’s one of only three global COVID-19 vaccines to reach the elusive 90% threshold for vaccine efficacy (VE). Such a high VE should allow Novavax to become a staple for booster shots in developed countries, as well as initial inoculations in emerging markets.

Equally intriguing is the potential Novavax offers in developing combination vaccines (e.g., influenza and COVID-19). Whereas Novavax trailed competitors when it brought its COVID-19 vaccine to market, it could be one of the first (if not the first) to bring a combo vaccine to pharmacy shelves.

You can pick up shares of Novavax for a little over two times Wall Street’s forecast earnings in 2022. Image source: Getty Images. Palantir Technologies

A third exceptional growth stock you’ll regret not scooping up on the Nasdaq bear market dip is data-mining company Palantir Technologies ( PLTR 5.86%). Despite previously trading at nosebleed multiples to its sales and adjusted earnings — Palantir’s shares are down more than 80% from its all-time high — it has all the tools necessary to make patient investors richer.

What makes Palantir such […]

source Nasdaq Bear Market: 4 Exceptional Growth Stocks You’ll Regret Not Buying on the Dip

editor Stocks , , ,

Leave a Reply